Recent Advances (2015–2020) in Drug Discovery for Attenuation of Pulmonary Fibrosis and COPD
A Dorababu, M Maraswami - Molecules, 2023 - mdpi.com
A condition of scarring of lung tissue due to a wide range of causes (such as environmental
pollution, cigarette smoking (CS), lung diseases, some medications, etc.) has been reported …
pollution, cigarette smoking (CS), lung diseases, some medications, etc.) has been reported …
British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
D Smith, IA Du Rand, C Addy… - BMJ open …, 2020 - bmjopenrespres.bmj.com
The full British Thoracic Society (BTS) guideline for the use of long-term macrolides in adults
with respiratory disease is published in Thorax. The following is a summary of the …
with respiratory disease is published in Thorax. The following is a summary of the …
Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD
R Bowler, M Allinder, S Jacobson… - BMJ Open …, 2019 - bmjopenrespres.bmj.com
Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease
characterised by airflow obstruction and other morbidities such as respiratory symptoms …
characterised by airflow obstruction and other morbidities such as respiratory symptoms …
Notch promotes DNMT-mediated hypermethylation of Klotho leads to COPD-related inflammation
J Qiu, YN Zhang, X Zheng, P Zhang… - Experimental Lung …, 2018 - Taylor & Francis
Aim: Klotho expression significantly declines in alveolar macrophages and airway epithelial
cells in chronic obstructive pulmonary disease (COPD) patients, and cigarette smoke extract …
cells in chronic obstructive pulmonary disease (COPD) patients, and cigarette smoke extract …
Association of Elevated Serum GM‐CSF, IFN‐γ, IL‐4, and TNF‐α Concentration with Tobacco Smoke Induced Chronic Obstructive Pulmonary Disease in a South …
Background. Chronic obstructive pulmonary disease (COPD) is a devastating condition with
limited pharmacotherapeutic options and exceptionally high public‐health burden globally …
limited pharmacotherapeutic options and exceptionally high public‐health burden globally …
Effect of smoking and its cessation on the transcript profile of peripheral monocytes in COPD patients
A Trivedi, G Bade, K Madan… - … Journal of Chronic …, 2022 - Taylor & Francis
Rationale Smoking is the primary cause of chronic obstructive pulmonary disease (COPD);
however, only 10–20% of smokers develop the disease suggesting possible genomic …
however, only 10–20% of smokers develop the disease suggesting possible genomic …
Identification and characterization of degradation products of indacaterol using liquid chromatography/mass spectrometry
NV Yerra, SB Dadinaboyina… - … Journal of Mass …, 2020 - journals.sagepub.com
Indacaterol (IND), 5-[2-[(5, 6-Diethyl-2, 3-dihydro-1H-inden-2-yl) amino]-1-hydroxyethyl]-8-
hydroxyquinolin-2 (1H)-one, is an active pharmaceutical ingredient (API) which is used to …
hydroxyquinolin-2 (1H)-one, is an active pharmaceutical ingredient (API) which is used to …
[HTML][HTML] Effect of herbal medicine formulation (compound honey syrup) on quality of life in patients with COPD: a randomized clinical trial
Z Poursaleh, R Choopani, E Vahedi, AF Khedmat… - Tanaffos, 2022 - ncbi.nlm.nih.gov
Background: Chronic obstructive pulmonary disease (COPD) as one of the health-
threatening problems imposes many economic costs on health systems. Today, there is a …
threatening problems imposes many economic costs on health systems. Today, there is a …
A Novel Upper-extremity Sensor-based Approach to Predict COPD Adverse Outcomes in an Acute Setting
M Asghari, P Rudy, M Peña, M Ruiz, S Parthasarathy… - CHEST Pulmonary, 2024 - Elsevier
Decisions about the intensity of treatment for patients with chronic obstructive pulmonary
disease (COPD) are influenced by the ability to predict upcoming adverse outcomes after …
disease (COPD) are influenced by the ability to predict upcoming adverse outcomes after …
Минимизация стоимости применения комбинированных лекарственных препаратов вилантерол+ умеклидиния бромид и олодатерол+ тиотропия бромид …
ЕГ Косолапов, ФС Коченков, НЛ Погудина… - Фармакоэкономика …, 2017 - cyberleninka.ru
В практику вошли современные комбинированные лекарственные препараты (ЛП) для
лечения хронической обструктивной болезни легких (ХОБЛ) на основе длительно …
лечения хронической обструктивной болезни легких (ХОБЛ) на основе длительно …